tetano
Editor, Senior Moderator
Viruses
. 2021 Jul 20;13(7):1411.
doi: 10.3390/v13071411.
Antiviral Effect of Budesonide against SARS-CoV-2
Natalie Heinen[SUP] 1 [/SUP], Toni Luise Meister[SUP] 1 [/SUP], Mara Klöhn[SUP] 1 [/SUP], Eike Steinmann[SUP] 1 [/SUP], Daniel Todt[SUP] 1 2 [/SUP], Stephanie Pfaender[SUP] 1 [/SUP]
Affiliations
Abstract
Treatment options for COVID-19, a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, antiviral drugs that efficiently reduce SARS-CoV-2 replication or alleviate COVID-19 symptoms are urgently needed. Inhaled glucocorticoids are currently being discussed in the context of treatment for COVID-19, partly based on a previous study that reported reduced recovery times in cases of mild COVID-19 after inhalative administration of the glucocorticoid budesonide. Given various reports that describe the potential antiviral activity of glucocorticoids against respiratory viruses, we aimed to analyze a potential antiviral activity of budesonide against SARS-CoV-2 and circulating variants of concern (VOC) B.1.1.7 (alpha) and B.1.351 (beta). We demonstrate a dose-dependent inhibition of SARS-CoV-2 that was comparable between all viral variants tested while cell viability remains unaffected. Our results are encouraging as they could indicate a multimodal mode of action of budesonide against SARS-CoV-2 and COVID-19, which could contribute to an improved clinical performance.
Keywords: SARS-CoV-2; antivirals; budesonide; corticosteroids; variants of concern.
. 2021 Jul 20;13(7):1411.
doi: 10.3390/v13071411.
Antiviral Effect of Budesonide against SARS-CoV-2
Natalie Heinen[SUP] 1 [/SUP], Toni Luise Meister[SUP] 1 [/SUP], Mara Klöhn[SUP] 1 [/SUP], Eike Steinmann[SUP] 1 [/SUP], Daniel Todt[SUP] 1 2 [/SUP], Stephanie Pfaender[SUP] 1 [/SUP]
Affiliations
- PMID: 34372616
- DOI: 10.3390/v13071411
Abstract
Treatment options for COVID-19, a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, are currently severely limited. Therefore, antiviral drugs that efficiently reduce SARS-CoV-2 replication or alleviate COVID-19 symptoms are urgently needed. Inhaled glucocorticoids are currently being discussed in the context of treatment for COVID-19, partly based on a previous study that reported reduced recovery times in cases of mild COVID-19 after inhalative administration of the glucocorticoid budesonide. Given various reports that describe the potential antiviral activity of glucocorticoids against respiratory viruses, we aimed to analyze a potential antiviral activity of budesonide against SARS-CoV-2 and circulating variants of concern (VOC) B.1.1.7 (alpha) and B.1.351 (beta). We demonstrate a dose-dependent inhibition of SARS-CoV-2 that was comparable between all viral variants tested while cell viability remains unaffected. Our results are encouraging as they could indicate a multimodal mode of action of budesonide against SARS-CoV-2 and COVID-19, which could contribute to an improved clinical performance.
Keywords: SARS-CoV-2; antivirals; budesonide; corticosteroids; variants of concern.